False-negative 18F-PSMA-1007 PET/CT in metastatic prostate cancer related to high physiologic liver uptake

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19(6):825–33.

    CAS  Article  Google Scholar 

  2. 2.

    Thang SP, Violet J, Sandhu S, Iravani A, Akhurst T, Kong G, et al. Poor outcomes for patients with metastatic castration-resistant prostate cancer with low prostate-specific membrane antigen (PSMA) expression deemed ineligible for (177)Lu-labelled PSMA radioligand therapy. Eur Urol Oncol. 2018.

  3. 3.

    Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44(4):678–88.

    CAS  Article  Google Scholar 

  4. 4.

    Kessel K, Seifert R, Schafers M, Weckesser M, Schlack K, Boegemann M, et al. Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving (177)Lu-PSMA-617. Theranostics. 2019;9(17):4841–8.

    CAS  Article  Google Scholar 

  5. 5.

    Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, et al. EANM procedure guidelines for radionuclide therapy with (177)Lu-labelled PSMA-ligands ((177)Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019.

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Constantin Lapa.

Ethics declarations

Informed consent from the patient for publication of this case study was obtained.

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Oncology – Genitourinary

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hartrampf, P.E., Seitz, A.K., Krebs, M. et al. False-negative 18F-PSMA-1007 PET/CT in metastatic prostate cancer related to high physiologic liver uptake. Eur J Nucl Med Mol Imaging 47, 2044–2046 (2020). https://doi.org/10.1007/s00259-019-04645-5

Download citation